Latest / DDReg Knowledge Capsule / South Korea MFDS Drug Registration: 2026 Updates and Approval Guide

Transcript

South Korea MFDS Drug Registration: 2026 Updates and Approval Guide · DDReg Knowledge Capsule

• 0:00
  Speaker 1: Welcome to deedra acknowledged capsule. Imagine having a breakthrough life
• 0:04
  Speaker 1: saving oncology drug. The FDA has cleared it, the EMA
• 0:08
  Speaker 1: has rigorously evaluated it, and you are ready for market.
• 0:12
  Speaker 2: Right, You've got the global green lane exactly.
• 0:14
  Speaker 1: But then you look at South Korea. This is a
• 0:16
  Speaker 1: pharmaceutical market value to over thirty billion dollars and it's
• 0:19
  Speaker 1: expanding rapidly.
• 0:21
  Speaker 2: Yeah, it's a massive opportunity.
• 0:22
  Speaker 1: But historically the regulatory authorities there would essentially tell you, well,
• 0:27
  Speaker 1: your global data just isn't enough, right. You practically had
• 0:30
  Speaker 1: to start from scratch running domestic clinical trials on Korean soil,
• 0:35
  Speaker 1: specifically with Korean patients, just to prove what you already
• 0:38
  Speaker 1: knew from your global trials. For years, that was this
• 0:41
  Speaker 1: ultimate barrier to entry, it really was.
• 0:43
  Speaker 2: It functioned almost like this highly protective moat around the market.
• 0:48
  Speaker 2: I mean, the Ministry of Food and Drug Safety, the MFDs,
• 0:51
  Speaker 2: they've always maintained an incredibly sophisticated regulatory environment. Yeah, but
• 0:56
  Speaker 2: it was one that demanded foreign sponsors prove their worth
• 0:58
  Speaker 2: entirely on localized geographic terms.
• 1:01
  Speaker 1: Right their sandbox, their rules exactly.
• 1:04
  Speaker 2: It required immense capital and frankly years of redundant clinical
• 1:09
  Speaker 2: effort just to penetrate.
• 1:10
  Speaker 1: That market, which brings us to our focus today. We
• 1:13
  Speaker 1: are unpacking a massive twenty twenty six comprehensive guide published
• 1:17
  Speaker 1: by d dreg Pharma. It's titled South Korea MFDs Drug
• 1:22
  Speaker 1: Registration Key Updates and Approval Guide.
• 1:25
  Speaker 2: It's a fantastic document, so.
• 1:27
  Speaker 1: Detailed it really is. And the mission of our deep
• 1:30
  Speaker 1: dive today is to map out exactly how the MFDs
• 1:33
  Speaker 1: is aggressively dismantling that moat we just talked about.
• 1:36
  Speaker 2: Yeah, a landscape is shifting completely.
• 1:38
  Speaker 1: What we're seeing in twenty twenty six is this radical
• 1:41
  Speaker 1: streamlining of the path for global life saving medicines to
• 1:44
  Speaker 1: reach Korean patients.
• 1:45
  Speaker 2: It's a structural evolution, really a massive shift in regulatory trust.
• 1:49
  Speaker 1: And it kind of reminds me of like trying to
• 1:52
  Speaker 1: get into an exclusive VIP club right totally. Like in
• 1:55
  Speaker 1: the past, the bouncer at the door of the Korean
• 1:57
  Speaker 1: reulatory system didn't care if you were famous in New
• 1:59
  Speaker 1: York London. You had to prove you were cool enough
• 2:02
  Speaker 1: right there on the sidewalk, entirely on their terms, right.
• 2:04
  Speaker 2: By running those mandatory local clinical trials exactly.
• 2:09
  Speaker 1: But now in twenty twenty six, they've completely changed the
• 2:12
  Speaker 1: entry requirements. They're aligning with global standards, and we.
• 2:15
  Speaker 2: Should clarify the MFDs hasn't lowered its bar for safety
• 2:19
  Speaker 2: or efficacy, right, it's crucial, Definitely, They've simply recognized that
• 2:22
  Speaker 2: modern scientific analytics can bridge that gap between global populations.
• 2:27
  Speaker 2: And the primary engine driving this whole market opening is
• 2:30
  Speaker 2: their updated stance on clinical data acceptance.
• 2:33
  Speaker 1: Yeah, let's get into that. Because the era of the
• 2:36
  Speaker 1: mandatory domestic phase three trial is essentially over.
• 2:40
  Speaker 2: It really is.
• 2:40
  Speaker 1: With the MFDs fully codifying the ICCHE five guideline in
• 2:45
  Speaker 1: this twenty twenty six update, the default expectation has just
• 2:48
  Speaker 1: completely flipped.
• 2:50
  Speaker 2: Right, It's night and day.
• 2:51
  Speaker 1: The agency is explicitly stating that multinational phase three data
• 2:54
  Speaker 1: from trials anchored in the US, Europe or other diverse
• 2:57
  Speaker 1: regions is now the primary evidence base.
• 3:00
  Speaker 2: Yeah, but I think we have to acknowledge why that
• 3:02
  Speaker 2: old requirement existed in the first place. You know, the
• 3:04
  Speaker 2: historical rationale for demanding localized trials was actually entirely valid
• 3:08
  Speaker 2: from a pharmacogenomic perspective.
• 3:10
  Speaker 1: Okay, unpack that a bit well.
• 3:12
  Speaker 2: Regulators were deeply concerned about how genetic variations might alter
• 3:15
  Speaker 2: a drugs profile, like differences in CYP four fifty liver
• 3:19
  Speaker 2: enzymes or varied receptor sensitivities that are specifically prevalent in
• 3:24
  Speaker 2: East Asian populations.
• 3:25
  Speaker 1: Right, Because how a drug metabolizes isn't always identical across
• 3:29
  Speaker 1: different ethnicities exactly.
• 3:30
  Speaker 2: They needed absolute certainty that a molecule metabolized safely in
• 3:35
  Speaker 2: say a largely Caucasian cohort, would perform identically in Seul.
• 3:39
  Speaker 1: But hold on, if they are abandoning that blanket requirement
• 3:42
  Speaker 1: for local trials, now, doesn't this massive shift risk missing
• 3:47
  Speaker 1: those actual genetic differences, Like how do they know how
• 3:50
  Speaker 1: Korean populations will process certain medications without that local data?
• 3:54
  Speaker 2: That's the key question, right, And the answer is that
• 3:56
  Speaker 2: the MFDs isn't just blindly accepting foreign data. They are
• 4:00
  Speaker 2: forcing the pharmaceutical sponsors to do all the analytical heavy
• 4:02
  Speaker 2: lifting upfront.
• 4:03
  Speaker 1: Ah okay, So what does that look like in practice?
• 4:06
  Speaker 2: It means the sponsor is now forced to present a
• 4:09
  Speaker 2: massive pharmacogenomic dossier. Eight. Right at the start, you have
• 4:13
  Speaker 2: to prove at a molecular and metabolic level that ethnic
• 4:16
  Speaker 2: differences won't skew the efficacy or safety profiles.
• 4:20
  Speaker 1: So instead of just running a local trial to see
• 4:22
  Speaker 1: what happens, you have to prove why it's not necessary.
• 4:26
  Speaker 2: Exactly, you have to comprehensively characterize the drugs mechanism of action,
• 4:30
  Speaker 2: its absorption, distribution, metabolism and excretion pathways within the initial submission.
• 4:35
  Speaker 1: So they're digging into the early phase PK and PD data.
• 4:38
  Speaker 2: Right, pharmacokinetic and pharmacodynamic data, plus robust scientific literature to
• 4:43
  Speaker 2: demonstrate that the compound is not subject to meaningful ethnic sensitivities.
• 4:48
  Speaker 2: So science, not geography, dictates the need for local trials.
• 4:51
  Speaker 1: Okay, So a Korean specific bridging study is only triggered
• 4:55
  Speaker 1: if the science actually points to a vulnerability. Yes, precisely,
• 4:58
  Speaker 1: like if your product targets disease with materially different population
• 5:02
  Speaker 1: level characteristics in Korea, right.
• 5:04
  Speaker 2: Or if the metabolic pathway is known to be highly
• 5:06
  Speaker 2: polymorphic across different ethnicities. In those specific cases, the MFDs
• 5:11
  Speaker 2: will absolutely still demand that local data.
• 5:13
  Speaker 1: But for the vast majority of globally developed therapeutics, you're
• 5:17
  Speaker 1: essentially bypassing years of clinical redundancy.
• 5:20
  Speaker 2: Yeah, and the strategic implications for global portfolio planning are massive.
• 5:25
  Speaker 2: By accepting the structural integrity of a multinational trial, the
• 5:28
  Speaker 2: MFTs is aligning Korean regulatory timelines and commercialization costs much
• 5:33
  Speaker 2: more closely with other major global markets.
• 5:35
  Speaker 1: Which is huge for developers. And you know, if the
• 5:39
  Speaker 1: MFDs is willing to trust the scientific validity of a
• 5:42
  Speaker 1: multinational Phase three trial to establish efficacy, the logical extension
• 5:46
  Speaker 1: is that they'd also trust the regulatory decisions of other
• 5:49
  Speaker 1: Tier one agencies absolutely. And we're seeing this exact dynamic
• 5:53
  Speaker 1: playing out with the twenty twenty six expansion of the
• 5:55
  Speaker 1: conditional approval pathway. This is specifically for urgent un medical needs.
• 6:01
  Speaker 2: Yeah. This revised framework for conditional approval is fascinating. It
• 6:04
  Speaker 2: closely mirrors the underlying philosophy of the FDA's Accelerated Approval
• 6:08
  Speaker 2: or the MMA's Conditional Marketing Authorization. The MFDs has laid
• 6:12
  Speaker 2: out specific eligibility criteria for diseases where patients simply cannot
• 6:17
  Speaker 2: afford to wait for standard multi year clinical endpoints to mature.
• 6:21
  Speaker 1: So what are those criteria? The DDRAG guide mentions three
• 6:24
  Speaker 1: main ones I.
• 6:25
  Speaker 2: Believe, right, So the first two are pretty standard for
• 6:27
  Speaker 2: the industry. One, the drug targets a serious or life
• 6:31
  Speaker 2: threatening condition with no existing improved treatment in Korea.
• 6:34
  Speaker 1: Makes total sense.
• 6:34
  Speaker 2: And two, the clinical data demonstrates a highly favorable benefit
• 6:39
  Speaker 2: risk profile based on validated surrogate endpoints.
• 6:42
  Speaker 1: Like relying on progression free survival in an oncology trial
• 6:47
  Speaker 1: rather than reading years for overall survival data.
• 6:50
  Speaker 2: Exactly. But the third criterion highlighted in the guide, this
• 6:54
  Speaker 2: is a massive leap in international regulatory reliance. What is
• 6:58
  Speaker 2: it a product can now secure can additional approval in
• 7:01
  Speaker 2: Korea if it is already conditionally or fully approved in
• 7:03
  Speaker 2: the US, the EU or Japan for that exact same indication.
• 7:07
  Speaker 1: Wait, really just based on the fact that the FDA
• 7:10
  Speaker 1: or EMA approved it.
• 7:11
  Speaker 2: Well as a primary lever for domestic fast tracking. Yes,
• 7:15
  Speaker 2: it's a profound indicator of harmonization. The MFDs reviewers are
• 7:19
  Speaker 2: fundamentally acknowledging the stringent review processes of those foreign agencies.
• 7:23
  Speaker 1: Okay, I have to push back on this a bit.
• 7:24
  Speaker 2: Go forth.
• 7:25
  Speaker 1: Approving a drug based on quote unquote surrogate endpoints or
• 7:30
  Speaker 1: just because the FDA approved it sounds a little bit
• 7:32
  Speaker 1: like copying a smart kid's homework.
• 7:34
  Speaker 2: Oh, that's a good way to put it.
• 7:36
  Speaker 1: I mean, how does the MFDs ensure they aren't letting
• 7:39
  Speaker 1: unsafe drugs slip through? Because relying on a surrogate endpoint
• 7:43
  Speaker 1: inherently introduces a degree of clinical uncertainty.
• 7:46
  Speaker 2: Right, it does, It absolutely does. But you have to
• 7:48
  Speaker 2: remember the conditional pathway is effectively a period of highly
• 7:52
  Speaker 2: monitored probation. It's not a permanent hall pass.
• 7:56
  Speaker 1: Okay.
• 7:56
  Speaker 2: The twenty twenty six framework explicitly mandates that sponsors submit
• 8:00
  Speaker 2: an uncompromising time bound plan for post market confirmatory studies.
• 8:05
  Speaker 1: So they can just promise to get more data eventually
• 8:07
  Speaker 1: and then drag their feet.
• 8:08
  Speaker 2: No, not at all. The MFDs requires clearly defined milestones
• 8:12
  Speaker 2: for interim statistical analyzes and a hard, non negotiable deadline
• 8:16
  Speaker 2: for the final clinical study report.
• 8:18
  Speaker 1: And what happens if they miss those deadlines?
• 8:20
  Speaker 2: The stakes are existential for the product if a sponsor
• 8:22
  Speaker 2: fails to execute the confirmatory study on time, or even worse,
• 8:26
  Speaker 2: if the final overall survival data fails to confirm the
• 8:28
  Speaker 2: initial promise shown by the surrogate endpoint.
• 8:31
  Speaker 1: They pulled the plug.
• 8:32
  Speaker 2: Immediate suspension or full revocation of the marketing authorization.
• 8:36
  Speaker 1: Wow.
• 8:36
  Speaker 2: Yeah, it's a calculated regulatory risk. They are balancing immediate
• 8:41
  Speaker 2: patient access against this strict, rigorous enforcement of post market validation.
• 8:46
  Speaker 1: I imagine the infrastructure required to manage all those post
• 8:49
  Speaker 1: market commitments is just immense.
• 8:51
  Speaker 2: It is. But this evolution of trust isn't just restricted
• 8:55
  Speaker 2: to novel small molecules or new biological entities. The push
• 8:59
  Speaker 2: toward global scientific harmonization is fundamentally rewriting the playbook for
• 9:04
  Speaker 2: highly complex modalities too.
• 9:06
  Speaker 1: You're talking about the biosimilar and digital health sectors exactly.
• 9:10
  Speaker 2: The rules there are transforming just as profoundly.
• 9:13
  Speaker 1: Let's talk about biosimilars first, because South Korea is already
• 9:17
  Speaker 1: a dominant global player in domestic biologics manufacturing.
• 9:20
  Speaker 2: They are a powerhouse.
• 9:21
  Speaker 1: So when the MFDs updates its biosimilar framework, they aren't
• 9:25
  Speaker 1: just reacting to global trends, they are actively shaping the
• 9:28
  Speaker 1: regulatory ceiling. The dd RED guide points out a monumental
• 9:31
  Speaker 1: shift for twenty twenty six. They are aligning their guidelines
• 9:35
  Speaker 1: closely with the EMA and the ICHQ eleven principles, and
• 9:39
  Speaker 1: the massive update here. The headline is that clinical efficacy
• 9:43
  Speaker 1: studies for biosimilars can actually be waived entirely.
• 9:46
  Speaker 2: Waving the phase three equivalence trial is basically the holy
• 9:50
  Speaker 2: grail for a biosimilar developer. Yeah, it's huge, the MFDs
• 9:54
  Speaker 2: stating that if the structural, physico chemical and functional analytical
• 9:58
  Speaker 2: similarity package is robust enough, a comparative clinical trial becomes
• 10:02
  Speaker 2: scientifically redundant.
• 10:03
  Speaker 1: It's like perfectly reverse engineering a Michelin star chef's famous
• 10:07
  Speaker 1: cake recipe in.
• 10:08
  Speaker 2: A las okay. I like this analogy, right, Like if.
• 10:10
  Speaker 1: You use mass spectrometry and advanced binding essays to prove
• 10:14
  Speaker 1: that every single molecule of your flour, your sugar, your
• 10:17
  Speaker 1: butter is structurally and functionally identical to the original cake, right,
• 10:21
  Speaker 1: you shouldn't have to go and feed it to a
• 10:22
  Speaker 1: thousand people in a clinical trial. Tastes the same or
• 10:25
  Speaker 1: has the exact same metabolic effect.
• 10:27
  Speaker 2: That is exactly it. The analytical precision available today allows
• 10:31
  Speaker 2: developers to validate molecular structure and target binding with such
• 10:35
  Speaker 2: high fidelity that any residual uncertainty about clinical performance is
• 10:39
  Speaker 2: practically negligible.
• 10:41
  Speaker 1: So if the structure in the impurity profiles match the
• 10:44
  Speaker 1: originator perfectly. It's going to perform identically in the human
• 10:47
  Speaker 1: body exactly.
• 10:48
  Speaker 2: And for an international biosimilar developer who is already building
• 10:52
  Speaker 2: this high density analytical package to satisfy the EMA in Europe,
• 10:56
  Speaker 2: this specific rule slashes the marginal cost of adding South
• 10:59
  Speaker 2: Korea to their launch sequence.
• 11:01
  Speaker 1: Because the data package is already across compatible YEP.
• 11:03
  Speaker 2: But the d dereg guide also flags a totally different
• 11:06
  Speaker 2: regulatory frontier, which is software as a medical device or
• 11:10
  Speaker 2: SMD right digital therapeutics.
• 11:12
  Speaker 1: This area is completely challenging the traditional boundaries of regulatory review.
• 11:17
  Speaker 2: It really is. We're seeing software algorithms functioning as active
• 11:21
  Speaker 2: therapeutic interventions or these highly complex drug device combinations where
• 11:26
  Speaker 2: an app on your phone dynamically controls the dosing of
• 11:29
  Speaker 2: a biologic.
• 11:30
  Speaker 1: And the classification blur. There must be a nightmare for
• 11:33
  Speaker 1: regulatory affairs teams. I mean, you can't just file an
• 11:36
  Speaker 1: algorithm driven insulin delivery system as a standard pharmaceutical product.
• 11:41
  Speaker 2: No, you can't. And the twenty twenty six MFDs framework
• 11:44
  Speaker 2: acknowledges this complexity by establishing a new combined regulatory pathway.
• 11:49
  Speaker 1: How does that work?
• 11:50
  Speaker 2: Sponsors are now required to engage in simultaneous cross divisional navigation,
• 11:55
  Speaker 2: so they have to interface explicitly with both the drug
• 11:57
  Speaker 2: assessment and the medical device review arms of the MFDs
• 12:01
  Speaker 2: right from the very beginning of development.
• 12:03
  Speaker 1: That makes sense. But with all these modernized frameworks reducing
• 12:07
  Speaker 1: the clinical burden waving trials excepting foreign data, a listener
• 12:10
  Speaker 1: might think that approval in Korea is effortless.
• 12:13
  Speaker 2: Now, oh, that is the danger here, assuming that scientific
• 12:16
  Speaker 2: harmonization equates to administrative ease.
• 12:19
  Speaker 1: Right, Let's transition to the procedural reality of actually filing
• 12:22
  Speaker 1: the submission. Because surviving the science is one thing, surviving
• 12:26
  Speaker 1: the paperwork as another.
• 12:27
  Speaker 2: The clinical burden is demonstrably lighter, yes, but compiling, translating,
• 12:32
  Speaker 2: and defending the actual submission remains a formidable administrative gauntlet.
• 12:36
  Speaker 1: Let's break down the mechanics. The submission flows through their
• 12:40
  Speaker 1: electronic portal called ez DR'D, which supports the standard ECTD format,
• 12:46
  Speaker 1: and the language requirements are bifurcated Module one, which is
• 12:50
  Speaker 1: all the regional administrative documents, localized risk management plans, the
• 12:54
  Speaker 1: prescribing info that absolutely must be offered in Korean no
• 12:58
  Speaker 1: exceptions there, but Modules two through five, which contained the
• 13:01
  Speaker 1: dense clinical, non clinical and quality data sets. Those are
• 13:05
  Speaker 1: generally accepted in English.
• 13:06
  Speaker 2: They are, But the true friction point emerges when you
• 13:10
  Speaker 2: look at the review timelines.
• 13:11
  Speaker 1: Okay, let's look at the math here, because the dd
• 13:13
  Speaker 1: RED guide highlights a massive timeline.
• 13:16
  Speaker 2: Paradox, yes of it jarring.
• 13:18
  Speaker 1: The MFDs officially targets three hundred and twenty working days
• 13:21
  Speaker 1: for a standard New Drug Application review and one hundred
• 13:24
  Speaker 1: and eighty working days for a priority review.
• 13:26
  Speaker 2: Right, that's the official target.
• 13:28
  Speaker 1: But the guide notes that the practical on the ground
• 13:30
  Speaker 1: reality for securing an approval often stretches from eighteen to
• 13:34
  Speaker 1: thirty calendar months.
• 13:35
  Speaker 2: Wait.
• 13:36
  Speaker 1: If the official target is three hundred and twenty days,
• 13:39
  Speaker 1: which is roughly fifteen months, how on earth does that
• 13:41
  Speaker 1: stretch into thirty months? Are the reviewers just incredibly slow
• 13:46
  Speaker 1: or is something getting lost in translation?
• 13:48
  Speaker 2: It's not about them working slowly at all. The reviewers
• 13:51
  Speaker 2: are notoriously meticulous. The delay is actually engineered into the
• 13:55
  Speaker 2: system through a mechanism known as the clock stop.
• 13:58
  Speaker 1: The clock stop, Okay, how does that well?
• 14:00
  Speaker 2: That three hundred and twenty day target represents active, uninterrupted
• 14:03
  Speaker 2: review time, but the moment a reviewer identifies a gap
• 14:07
  Speaker 2: in the data or requires clarification, usually regarding Module three
• 14:10
  Speaker 2: quality sections or the justification for omitting that ethnic bridging
• 14:14
  Speaker 2: data we talked about. They issue a formal request for
• 14:17
  Speaker 2: supplementary information.
• 14:18
  Speaker 1: And what happens to the clock?
• 14:20
  Speaker 2: The official review countdown literally freezes on that exact day.
• 14:23
  Speaker 1: Wait, it pauses, entirely, pauses entirely.
• 14:26
  Speaker 2: If they issue a query on day one fourteen regarding say,
• 14:28
  Speaker 2: degradation impurities, the clock says at one fourteen, it does
• 14:31
  Speaker 2: not restart until pharmaceutical sponsor compiles, translates, and formally submits
• 14:35
  Speaker 2: a scientifically robust response.
• 14:37
  Speaker 1: Oh wow, And depending on the complexity of the query,
• 14:40
  Speaker 1: generating that new data could take a sponsor weeks or
• 14:43
  Speaker 1: even months of frantic internal scrambling.
• 14:46
  Speaker 2: Exactly, And that thirty month timeline is just the aggregate
• 14:51
  Speaker 2: reality of all those localized delays adding.
• 14:53
  Speaker 1: Up, which proves exactly why the pre consultation system is
• 14:57
  Speaker 1: so vital.
• 14:57
  Speaker 2: Yes, absolutely, the pre consultation is structurally vital.
• 15:01
  Speaker 1: The guide heavily emphasizes this. It requires an investment of
• 15:04
  Speaker 1: thirty to sixty calendar days before you even submit the
• 15:08
  Speaker 1: formal dossier.
• 15:09
  Speaker 2: Right. It allows the regulatory affairs team to sit down
• 15:12
  Speaker 2: with the assessors, walk through the complex data package, and
• 15:16
  Speaker 2: proactively identify the exact scientific vulnerabilities that would otherwise trigger
• 15:20
  Speaker 2: a clock stop later.
• 15:21
  Speaker 1: So, treating this pre submission meeting as optional is basically
• 15:24
  Speaker 1: a profound strategic error.
• 15:26
  Speaker 2: It will almost certainly cost you a year on the
• 15:28
  Speaker 2: back end. Proactive mitigation is really the only way to
• 15:31
  Speaker 2: compress that thirty month timeline back toward the three hundred
• 15:34
  Speaker 2: and twenty day target.
• 15:35
  Speaker 1: Yeah. So, let's say a sponsor survives this thirty month
• 15:37
  Speaker 1: administrative gauntlet. They avoid the clock stops, they secure their
• 15:41
  Speaker 1: marketing author as theation to celbrate fright. Well, getting the
• 15:44
  Speaker 1: approval is only half the battle. Now we have to
• 15:46
  Speaker 1: explore the physical realities of manufacturing the drug and keeping
• 15:49
  Speaker 1: it legally on the market.
• 15:50
  Speaker 2: Yeah, the challenge immediately shifts from data defense to physical
• 15:55
  Speaker 2: infrastructure and ongoing local safety compliance.
• 15:58
  Speaker 1: Let's talk about pharmacovid on rules first. Korea demands a
• 16:02
  Speaker 1: highly sophisticated always on safety reporting infrastructure. Do if there
• 16:07
  Speaker 1: is a serious unexpected adverse drug reaction, the marketing authorization
• 16:12
  Speaker 1: holder has exactly fifteen calendar days to report it to
• 16:15
  Speaker 1: the MFDs.
• 16:16
  Speaker 2: And beyond just reporting, there's the mandate for Risk Management
• 16:19
  Speaker 2: Plans or rmps for innovative medicines and biosimilars. This requires
• 16:24
  Speaker 2: deep localization.
• 16:25
  Speaker 1: Meaning you can't just take your EU risk management plan
• 16:28
  Speaker 1: translated into Korean and call it a day.
• 16:30
  Speaker 2: Definitely not. While the underlying structure aligns broadly with the
• 16:33
  Speaker 2: European format, the MFDs requires a specific Korean annex. This
• 16:38
  Speaker 2: has to detail localized pharmaco epidemiological data and bespoke domestic
• 16:43
  Speaker 2: safety mitigation activities. Okay, so heavy local compliance. But hold on,
• 16:48
  Speaker 2: there's something else in the DD guide that caught my eye.
• 16:51
  Speaker 2: The Good Manufacturing Practice or GMP divide.
• 16:55
  Speaker 1: Ah, yes, the GMP gap.
• 16:57
  Speaker 2: Earlier we said Korea implicitly trusts the FDA's clinical approvals
• 17:02
  Speaker 2: for the conditional pathway, but here the guide says they
• 17:05
  Speaker 2: won't legally recognize US manufacturing facilities without sending their own inspectors.
• 17:10
  Speaker 2: That seems entirely contradictory. They trust the FDA's clinical science
• 17:14
  Speaker 2: but not their factory inspections.
• 17:16
  Speaker 1: It does seem contradictory at first glance, but it beautifully
• 17:20
  Speaker 1: illustrates the fascinating difference between clinical harmonization and international geopolitics.
• 17:25
  Speaker 2: Okay, break that down from.
• 17:26
  Speaker 1: Me evaluating clinical trial methodology or accepting a surrogate endpoint.
• 17:30
  Speaker 1: That is a purely scientific assessment. It's made by pharmacologists
• 17:33
  Speaker 1: and toxicologists looking at data.
• 17:35
  Speaker 2: Right, science is science anywhere exactly.
• 17:37
  Speaker 1: But mutual recognition agreements or MRAs, which govern factory inspections,
• 17:42
  Speaker 1: those are highly complex bilateral trade treaties. They require years
• 17:46
  Speaker 1: of diplomatic negotiation to legally seed sovereign inspection authority from
• 17:50
  Speaker 1: one country to another. Oh I see So the European
• 17:53
  Speaker 1: Union has one of these MRAs with South Korea.
• 17:56
  Speaker 2: Yes, European manufacturers benefit from this umbrella. A biologic facility
• 18:01
  Speaker 2: in Germany passes an inspection by the EMA. The MFDs
• 18:05
  Speaker 2: legally recognizes that inspection and grants GMP clearance without ever
• 18:10
  Speaker 2: stepping foot in Europe.
• 18:11
  Speaker 1: But the US does not have an MRA with Korea
• 18:14
  Speaker 1: for pharmaceutical GMP exactly.
• 18:16
  Speaker 2: So an American pharmaceutical company must factory in the logistical friction,
• 18:19
  Speaker 2: the immense cost and the time required to host a
• 18:22
  Speaker 2: team of Korean inspectors physically at their US sites to
• 18:26
  Speaker 2: conduct a full facility audit.
• 18:28
  Speaker 1: Wow. So the science is harmonized, but the diplomacy is
• 18:31
  Speaker 1: still catching up.
• 18:31
  Speaker 2: Perfectly said, it's a unique hurdle that US companies facing
• 18:35
  Speaker 2: Korea compared to their European peers.
• 18:37
  Speaker 1: This has been incredibly insightful. Let me try to synthesize
• 18:40
  Speaker 1: this deep dive for our listeners. If you are operating
• 18:42
  Speaker 1: in the global pharma space, the twenty twenty six South
• 18:45
  Speaker 1: Korean market is no longer this isolated, idiosyncratic regulatory island.
• 18:50
  Speaker 1: It is an internationally aligned powerhouse. It highly rewards proactive
• 18:55
  Speaker 1: preparation over reactive scrambling. But as we saw with the
• 18:59
  Speaker 1: clock style, the localized rmps, and the GMP inspections, this
• 19:03
  Speaker 1: system still demands flawless procedural execution to actually realize the
• 19:07
  Speaker 1: benefits of that clinical harmonization.
• 19:10
  Speaker 2: The friction is really just moved from the clinic to
• 19:12
  Speaker 2: the administrative dossier. But the underlying trend here raises a
• 19:16
  Speaker 2: really profound structural question about the future of global drug development.
• 19:20
  Speaker 1: Oh what's that?
• 19:21
  Speaker 2: Well, if regional regulators like the MFDs, the EMA, and
• 19:25
  Speaker 2: the FDA are increasingly integrating ICH guidelines, trusting each other's
• 19:30
  Speaker 2: multinational Phase three data, and leveraging each other's regulatory decisions
• 19:34
  Speaker 2: to fastrack urgent approvals. Are we inevitably moving toward a
• 19:37
  Speaker 2: future with a single global marketing authorization for life saving drugs?
• 19:42
  Speaker 1: Oh? Wow? A unified, concurrent global launch based on a
• 19:45
  Speaker 1: single universally accepted data package. That would be incredible, That
• 19:50
  Speaker 1: would change everything. But I wonder, despite all this profound
• 19:53
  Speaker 1: scientific alignment, will the realities of national borders distinct localized
• 20:00
  Speaker 1: genetics and geopolitical treaties always require a final sovereign gatekeeper
• 20:05
  Speaker 1: for human health.
• 20:06
  Speaker 2: That is the central tension the industry is going to
• 20:08
  Speaker 2: have to navigate for the next decade.
• 20:09
  Speaker 1: Definitely something for our listeners to mull over. Thank you
• 20:12
  Speaker 1: all for joining us on this deep dive.
• 20:14
  Speaker 2: It has been a pleasure. Keep questioning the consensus until
• 20:17
  Speaker 2: next time.